Focus: Apellis Pharmaceuticals is a specialty pharma company headquartered in Australia, focused on complement inhibitor therapies for rare eye and kidney diseases. Now acquired by Biogen (May 2026), it operates as a mid-to-large biotech with revenue concentrated in two marketed products.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Growing — net +12 jobs in 30d
14 jobs added vs 2 removed. Steady team buildout.
Apellis offers meaningful therapeutic focus and pipeline depth in complement inhibition, but post-acquisition integration risk and single-product revenue dependency warrant careful evaluation of role stability and long-term career trajectory within Biogen.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship complement inhibitor driving 94% of company revenue; faces competition but maintains market presence through 2038.
Help build intelligence for Apellis Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Apellis Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Second marketed indication of pegcetacoplan with emerging uptake; contributes modest but growing revenue stream.
Apellis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Apellis Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data reveliolabs.com
8-K Filing: BridgeBio Pharma, Inc. (BBIO) (CIK 0001743881) — EXHIBIT 99.1
EXHIBIT 99.1
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover - Pharmaceutical Technology
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Pharmaceutical Technology
Global Health Headlines: Ebola, Pharmaceuticals, and Drug Regulations - Devdiscourse
Global Health Headlines: Ebola, Pharmaceuticals, and Drug Regulations Devdiscourse
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy - BioSpace
Layoff Tracker: Biogen axes ‘small number’ of Apellis roles after $5.6B buy BioSpace
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times Europe
Biogen completes acquisition of Apellis Pharmaceuticals Ophthalmology Times Europe
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent acquisition-triggered layoffs indicate structural redundancy and integration risk; employees should assess role essentiality within Biogen's complement-inhibitor portfolio before committing.
Recent peer-reviewed publications with author affiliations at this company
Expert Opinion: Management of Intraocular Inflammation and Vasculitis After Intravitreal Pegcetacoplan for Geographic Atrophy.
Pathologic evaluation of pig kidney and heart xenografts: 2024 recommendations from the Banff Xenotransplantation Pathology Working Group.
+1 more
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo